罗米司亭用于自体造血细胞移植后血小板减少症的开放标签先导研究
本研究为开放标签、单臂先导研究,评估罗米司亭促进多发性骨髓瘤或淋巴瘤患者自体造血细胞移植后血小板恢复的效果。与853例未使用罗米司亭的回顾性对照相比,59例罗米司亭治疗患者血小板恢复至正常值的时间约从第+15天开始增强,第+21天和第+30天血小板计数平均分别高40×10^9/L和118×10^9/L,但4级血小板减少天数、输血需求等无差异。仅1例不良事件(低危肺栓塞)可能与罗米司亭相关。
要点
- 罗米司亭从移植后第+1天开始每周给药,至血小板计数>50×10^9/L且无需输血。
- 匹配队列多变量分析显示,第+21天血小板计数平均高40×10^9/L(95%CI 14-67,P=.003)。
- 第+30天血小板计数平均高118×10^9/L(95%CI 84-152,P<.001),但改善出现晚于缩短血小板低谷的目标。
核心结论
- 罗米司亭在自体造血细胞移植后显示出有前景的活性和安全性,但血小板计数的改善出现时间晚于缩短血小板低谷持续时间和深度的目标。
研究设计与样本
- 开放标签、单臂先导研究,纳入多发性骨髓瘤或淋巴瘤接受自体造血细胞移植的患者,罗米司亭组59例, contemporaneous回顾性未使用罗米司亭对照853例。
主要发现
- 罗米司亭组与未使用罗米司亭组在4级血小板减少天数、需输血天数、血小板植入时间和自体移植期间血小板输注数量方面相似。
- 罗米司亭组血小板恢复至正常值从大约第+15天开始增强。
- 匹配队列多变量分析中,与未使用罗米司亭相比,罗米司亭治疗与第+21天血小板计数平均高40×10^9/L(95%CI 14-67,P=.003)和第+30天平均高118×10^9/L(95%CI 84-152,P<.001)相关。
- 仅1例不良事件被认为可能与罗米司亭相关:1例多发性骨髓瘤患者发生低危肺栓塞。
关键数值与推荐
- 所有患者从自体造血细胞移植后第+1天开始每周接受罗米司亭治疗,直至血小板计数>50×10^9/L且无需输血。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There are no standard treatments to prevent or hasten the recovery from severe conditioning-regimen-induced thrombocytopenia occurring after autologous hematopoietic cell transplantation (auto-HCT). We conducted an open-label, single-arm pilot study of romiplostim, a thrombopoietin receptor agonist, to enhance platelet recovery in patients with multiple myeloma or lymphoma undergoing auto-HCT. All patients were treated weekly with romiplostim starting day +1 after auto-HCT until the platelet count was >50 × 109/L without transfusion. Compared with contemporary retrospective data from romiplostim-naïve patients (N = 853), romiplostim-treated patients (N = 59) had a similar median number of days of grade 4 thrombocytopenia or days requiring transfusions, time to platelet engraftment, and number of platelets transfusions during the auto-HCT. However, romiplostim-treated patients had enhanced platelet recovery to normal values beginning at approximately day +15. In matched cohort multivariable analyses, romiplostim treatment was associated with higher platelet counts by an average of 40 × 109/L (95% confidence interval (CI) (14, 67), P = .003) and 118 × 109/L (95% CI [84, 152], P<.001) at days +21 and +30, respectively, compared with those of no romiplostim. Only 1 adverse event was deemed possibly attributable to romiplostim: a low-risk pulmonary embolism in a patient with multiple myeloma. In conclusion, romiplostim showed promising activity and safety after auto-HCT, but the improvement in platelet counts occurred later than the goal of shortening the duration and depth of the platelet nadir. This trial was registered at www.clinicaltrials.gov (#NCT04478123).
引用
- Scordo M, Gilbert LJ, Hanley DM, et al. Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation. Blood Adv. 2023. PMID: 36409612. doi:10.1182/bloodadvances.2022007838
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。